COMP <GO>
ONCY vs CLNN // OPERATING MARGIN
Oncolytics Biotech Inc. (NASDAQ) VS. Clene Inc. (NASDAQ) • 15-METRIC TALLY: ONCY 1
— CLNN 2
■ METRIC PARITY
LAST: $0.43 (-0.54%) • MKT CAP: $56.1M
operating-margins
—
LAST: $3.83 (-1.79%) • MKT CAP: $55.4M
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ONCY VS. CLNN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ONCY | CLNN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 78.50% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -41.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | CLNN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.1 | 49.4 | -25.31 | CLNN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $56.1M | $55.4M | $645.8K | ONCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ONCY REV | CLNN REV | ONCY GROSS % | CLNN GROSS % | ONCY FCF | CLNN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $200.0K | — | 78.5% | -$20.1M | -$18.6M |
| FY 2024 | $0 | $342.0K | — | 79.5% | -$20.1M | -$21.3M |
| FY 2023 | — | $654.0K | — | — | — | -$30.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ONCY // BETA —
CLNN // BETA —